Navigation Links
Covance and Lilly Finalize 10-Year, $1.6 Billion Strategic R&D Collaboration
Date:10/3/2008

PRINCETON, N.J., Oct. 3 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD), one of the world's largest and most comprehensive drug development services companies, today announced that it has closed its transaction with Eli Lilly and Company to provide a broad-range of drug development services over the next ten years and to purchase Lilly's 450-acre early drug development campus in Greenfield, Indiana. Effective midnight tonight, Covance will assume control of the Greenfield campus and 264 Lilly employees will be working for Covance.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.5 billion, global operations in more than 20 countries, and more than 9,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at http://www.covance.com.


'/>"/>
SOURCE Covance Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Covance Inc. Invites You to Join the Webcast of Its Third Quarter 2007 Financial Results Conference Call
2. Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
3. Covance to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. Covance to Present at The R.W. Baird 2008 Growth Stock Conference
5. Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China
6. Covance Decides to Pursue Its Original Preclinical Strategy in China
7. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
8. Lilly Declares Fourth-Quarter Dividend
9. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
10. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
11. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , ... August 15, 2017 , ... Any expert in ... has compromised these disciplines for more than half a century. Despite their essential ... It is widely known that molecular tags developed for this purpose also tag ...
(Date:8/15/2017)... New York, NY (PRWEB) , ... August 15, 2017 , ... ... for the first time on Immuno-Oncology 360° (IO360°) programming through a series of upcoming ... to be held February 7-9, 2018, at The Roosevelt Hotel in New York City. ...
(Date:8/15/2017)... ... August 15, 2017 , ... JULABO USA introduces ... the new website makes it easy to navigate through the site whether you’re ... find detailed product information, educational industry content and visit the company’s social media ...
(Date:8/14/2017)... ... August 14, 2017 , ... ... interconnect using USB or PCI Express, announced the release of SYZYGY™, a new ... to satisfy the need for a compact, low cost, low pin-count, high-performance connectivity ...
Breaking Biology Technology:
(Date:6/30/2017)... Va. , June 30, 2017 ... leading developer and supplier of face and eye ... ATA Featured Product provider program. ... an innovative way to monitor a driver,s attentiveness ... greatly from being able to detect fatigue and ...
(Date:5/16/2017)... 16, 2017   Bridge Patient Portal , ... MD EMR Systems , an electronic medical ... GE, have established a partnership to build an ... the GE Centricity™ products, including Centricity Practice Solution ... These new integrations will allow healthcare delivery ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. (NASDAQ: ... announces the filing of its 2016 Annual Report on Form 10-K ... Commission. ... 10-K is available in the Investor Relations section of the Company,s ... the SEC,s website at http://www.sec.gov . 2016 Year ...
Breaking Biology News(10 mins):